ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,836.22
0.16%
US Tech 100
20,320.80
0.16%
Dow Jones
42,297.12
0.86%
Brent Oil
79.945
-0.42%
Bitcoin
94,948.14
0.47%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Guardant Health Inc (GH) Quote

Guardant Health Inc

Guardant Health Inc (GH)

Gamehost Inc
38.10
1.40
(3.80%)
Closed January 13 4:00PM
Delayed by 15 minutes
37.98
-0.12
(-0.31%)
After Hours: 7:19PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
37.98
Bid
37.61
Ask
38.49
Volume
2,954,568
35.68 Day's Range 38.33
15.81 52 Week Range 38.53
Market Cap
4.693B
Previous Close
36.705
Open
37.07
Last Trade
3
@
38.49
Last Trade Time
Financial Volume
$ 110,149,586
VWAP
37.2811
Average Volume (3m)
1,854,747
Shares Outstanding
123,554,612
Dividend Yield
-
PE Ratio
-9.82
Earnings Per Share (EPS)
-3.88
Revenue
563.95M
Net Profit
-479.45M

About Guardant Health Inc

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.guardanthealth.com
Headquarters
Dover, Delaware, USA
Founded
-
Guardant Health Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker GH. The last closing price for Guardant Health was $36.71. Over the last year, Guardant Health shares have traded in a share price range of $ 15.81 to $ 38.53.

Guardant Health currently has 123,554,612 shares outstanding. The market capitalization of Guardant Health is $4.54 billion. Guardant Health has a price to earnings ratio (PE ratio) of -9.82.

Ask ADVFN Intelligence (AI)

Guardant Health (GH) Options Flow Summary

GH Options Flow

Overall Flow

Bullish

Net Premium

65k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

GH Latest News

More News

Form 8-K - Current report

8 hours ago
Edgar (US Regulatory)

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today...

17 hours ago
Business Wire

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin Pilot study by National Cancer...

January 07 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

January 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
14.0812.035398230133.938.466333.9257633536.29645739CS
43.09018.8567178467134.889938.466329.91180772933.51962509CS
1216.6477.975632614821.3438.5320.14185474730.55235392CS
266.721.419437340231.2838.5320.14202855528.75378283CS
5214.1859.579831932823.838.5315.81202729625.75389071CS
156-47.2-55.412068560785.1885.8915.81170829632.72180557CS
260-40.66-51.703967446678.64181.0715.81142665454.36618403CS

GH - Frequently Asked Questions (FAQ)

What is the current Guardant Health share price?
The current share price of Guardant Health is $ 37.98
How many Guardant Health shares are in issue?
Guardant Health has 123,554,612 shares in issue
What is the market cap of Guardant Health?
The market capitalisation of Guardant Health is USD 4.54B
What is the 1 year trading range for Guardant Health share price?
Guardant Health has traded in the range of $ 15.81 to $ 38.53 during the past year
What is the PE ratio of Guardant Health?
The price to earnings ratio of Guardant Health is -9.82
What is the cash to sales ratio of Guardant Health?
The cash to sales ratio of Guardant Health is 8.35
What is the reporting currency for Guardant Health?
Guardant Health reports financial results in USD
What is the latest annual turnover for Guardant Health?
The latest annual turnover of Guardant Health is USD 563.95M
What is the latest annual profit for Guardant Health?
The latest annual profit of Guardant Health is USD -479.45M
What is the registered address of Guardant Health?
The registered address for Guardant Health is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Guardant Health website address?
The website address for Guardant Health is www.guardanthealth.com
Which industry sector does Guardant Health operate in?
Guardant Health operates in the MEDICAL LABORATORIES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PHIOPhio Pharmaceuticals Corporation
$ 6.50
(284.62%)
281.98M
SLRXSalarius Pharmaceuticals Inc
$ 3.65
(133.23%)
120.26M
VRMEVerifyMe Inc
$ 4.1575
(63.04%)
57.6M
ATPCAgape ATP Corporation
$ 1.9645
(55.91%)
84.16M
AVGRAvinger Inc
$ 0.8248
(46.47%)
9.78M
EHGOEshallgo Inc
$ 1.2408
(-62.06%)
6.74M
CMTLComtech Telecommunications Corporation
$ 2.3491
(-43.12%)
4.37M
SVMHSRIVARU Holding Ltd
$ 0.0352
(-43.04%)
184.27M
LAESSEALSQ Corporation
$ 3.35
(-41.54%)
89.92M
NMHINatures Miracle Holding Inc
$ 1.12
(-38.80%)
735.08k
GCTKGlucoTrack Inc
$ 0.1493
(27.61%)
685.02M
PHIOPhio Pharmaceuticals Corporation
$ 6.50
(284.62%)
281.98M
BHATBlue Hat Interactive Entertainment Technology
$ 0.0627
(-28.83%)
232.25M
NVDANVIDIA Corporation
$ 133.23
(-1.97%)
204.68M
RGTIRigetti Computing Inc
$ 6.0344
(-32.43%)
192.21M

GH Discussion

View Posts
Monksdream Monksdream 4 months ago
GH buy the dip
👍️0
Monksdream Monksdream 5 months ago
GH that awful Cathie has been a recent buyer
👍️0
x993231 x993231 6 months ago
I'm in, $33 ish I like the potential. Short wise only 6% of float and 6 million shares only 200 million so I don't think we'll see a squeeze like ASTS has been doing.

X. I just like to throw down a marker when I invest, I'm a long as in 80% of the time I hold shares for years and years many for decades.
👍️0
Monksdream Monksdream 7 months ago
The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]
👍️0
SubPenny0001 SubPenny0001 8 months ago
I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.
👍️0
Trooperstocks Trooperstocks 8 months ago
For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 💯 1
Trooperstocks Trooperstocks 8 months ago
$GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
👍️ 1 💪 1
Trooperstocks Trooperstocks 8 months ago
Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 😍 1
Trooperstocks Trooperstocks 8 months ago
$GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16 2024 - 8:05AM


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

“One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
👍️ 1 💯 1
DewDiligence DewDiligence 2 years ago
GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

EXAS is +24%/AH, adding about $2B(!) to its market cap.

In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.
👍️0
jerseyboy jerseyboy 4 years ago
I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
👍️0
jerseyboy jerseyboy 4 years ago
I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
👍️0
jerseyboy jerseyboy 4 years ago
So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
👍️0
PR_12 PR_12 4 years ago
2-3 years I'm thinking this is @ 3-5X current share price
👍️0

Your Recent History

NASDAQ
GH
Guardant Health
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads